FDA Regulatory Affairs: Operational Guidance for Clinical Development (Clinical Research & Regulatory Affairs)

Updated for 2026 to reflect current FDA regulations and clinical development practice.

FDA regulatory work requires a team to determine which source controls a decision and how the requirement applies to a specific product. The team also has to document the rationale before work moves forward. Statutes, 21 CFR, FDA guidance, center practice, product type, and lifecycle stage all matter. Problems usually start when teams rely on memory or informal interpretation, or when they document the rationale too late to guide the work.

FDA Regulatory Affairs: Operational Guidance for Clinical Development connects FDA expectations to clinical development work across the product lifecycle. The book explains how teams use statutes, 21 CFR, and guidance to build plans, controls, and documentation that can hold up under review.

The book covers drugs, biologics, and medical devices from premarket through postmarket. Topics include product classification and jurisdiction, regulatory pathways, FDA meeting strategy, quality systems, data integrity, clinical trial compliance, inspections and 483 response, safety reporting, pharmacovigilance, labeling and promotion, recalls and corrections, postmarket oversight, and regulatory intelligence.

Teams document regulatory decisions in protocols, submissions, plans, procedures, and quality records. Those decisions also affect inspection preparation, safety processes, and lifecycle controls.

This book is written for professionals and leaders working in clinical operations, regulatory affairs, quality, and project management. It is also for graduate students in those fields.

Readers can use the book to:
- Apply FDA primary sources to practical deliverables and clear ownership
- Plan pathway strategy across IND, IDE, NDA, BLA, 510(k), De Novo, PMA, and lifecycle changes
- Prepare FDA meetings and communications with a clear record that links each question to its rationale and final decision
- Build inspection-ready clinical, quality, and safety operations, including roles, escalation, and documentation discipline
- Support safety reporting and postmarket oversight by defining the reportability logic and timeline, then documenting each handoff
- Sustain compliance through change control, remediation, and recall or correction governance

The book can be read end to end for structure, then used as a working reference during planning, execution, and inspection preparation.